Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00750269 · ClinicalTrials.gov registry record · Phase 1
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT00750269 is a Phase 1 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 120 participants.
The verdict
NCT00750269, a Phase 1 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I/II trial is studying the side effects and best dose of stereotactic body radiation therapy and to see how well it works in treating patients with stage I non-small cell lung cancer.
Interventions
- RADIATION SBRT 40.0 Gy
- RADIATION SBRT 42.5 Gy
- RADIATION SBRT 45.0 Gy
- RADIATION SBRT 47.5 Gy
- RADIATION SBRT 50.0 Gy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2009-02 |
| Est. Completion | 2022-05-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00750269
The ClinicalTrials.gov registry entry for NCT00750269 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which SBRT 40.0 Gy is the first listed.
NCT00750269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00750269 about?
NCT00750269 is a clinical study titled "Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer". RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I/II trial is studying the side effects and best dose of stereotactic body radiation therapy and to see how well it works in treating patients ...
What is the current status of trial NCT00750269?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2009-02. Estimated completion is 2022-05-20.
What interventions are being tested in trial NCT00750269?
The interventions under investigation include: SBRT 40.0 Gy (RADIATION), SBRT 42.5 Gy (RADIATION), SBRT 45.0 Gy (RADIATION), SBRT 47.5 Gy (RADIATION), SBRT 50.0 Gy (RADIATION).
Who is sponsoring clinical trial NCT00750269?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.